RLS Radiopharmacies’ Post

Nuclear Medicine Europe is the professional association of companies active in the nuclear medicine field across the world (notwithstanding the "Europe" in its name). Its role in the currently ongoing revolution in the nuclear medicine field with promising new therapeutic options in cancer care in full development, cannot be overestimated. One of the major challenges the industry is facing is putting in place and securing the various supply chains and the logistics they require, not in the least the radioisotope supply. Given my experience in the domain, I would like to strongly advocate to spend money and time on making these supply chains independent from national and international subsidies and control, instead of asking oneself how subsidies and control can stabilise these chains. The ongoing boom in radiopharma offers an opportunity to correct mistakes from the past in which isotope production was left to national labs and heavily subsidized, creating a market which is now incapable of surviving without subsidies. The biggest example is the Mo-99 supply chain, which relies on a handful of ageing reactors throughout the world (>50% of it is coming from 2 reactors in Belgium and the Netherlands). It is vital that radiopharmaceuticals are accepted to have a COGS of 8-12% (compared to the typically much lower COGS of other pharma products) and in that sense allow radioisotope production to become commercially viable and sustainable. Allowing the market dynamics to play its role will improve the quality of service provided by the producers and will create a viable business case for the construction of dedicated isotope production reactors. Even without commercial reactors, assuring a proper margin for the production of these highly technological and life-saving ingredients of radiopharma can be achieved. If the reimbursement of the radioisotope is separated from the reimbursement of the pharmaceutical, the participation of all countries to the isotope production cost, proportional to their use of radiopharma products, will be assured. Today, the taxpayers of a few countries help fund the production of medical radioisotopes for the rest of the world, which is not sustainable... The NMEu will help us to address these and many other issues at a European and even global level, creating a hopeful future for cancer patients !

Should Australia look towards creating a radiopharmaceutical specific reimbursement pathway? As it currently stands there are both MSAC and PBAC avenues but the process is fragmented and poorly understood. The latest MSAC PSD gives clear evidence of this. With so much investment in nuclear medicine globally, is Australia at risk of falling behind? https://lnkd.in/gEg4AJg9

📰 It's News Wednesday on the Comecer website. In nuclear medicine, safety is critical to protect operators and patients from radioactive materials. Hot cells and microbiological safety hoods are essential for generating a safe environment when handling radiopharmaceuticals. 👉 Interested in how these technologies provide maximum protection? Read the full article! https://lnkd.in/dbHcDznt #ComcerNews #ComecerSolutions #NuclearMedicine

Balancing Nuclear Safety Principles and cGMP in Radiopharmaceutical Facilities When designing radiopharmaceutical facilities, the apparent contradictions between nuclear safety principles (where the goal is to keep contaminated air within the facility) and cGMP requirements (where the goal is to keep the product clean in pressurized areas) must be taken into account. An extensive knowledge of both regulations is essential. Progress - Experts in Life Sciences consultants work closely with you to develop optimized layouts that consider all critical flows: personnel, product, waste, utilities and air pressure. The focus is on achieving the most efficient and safe solution possible. https://lnkd.in/eQZsTkyC #GMP #FacilityDesign #SafetyFirst

Dose Calibrators: The Right Partners for Your Nuclear Medicine Department and Radiopharmaceutical Manufacturing Facilities. Comecer #DoseCalibrators are used worldwide in Nuclear Medicine Departments and Radiopharmaceutical Production Facilities to measure radiopharmaceuticals for both diagnostic and therapeutic use. Designed to measure radioactive patient doses to ensure the right dose is prepared for the right patient, they feature fully digital signal processing and are equipped with the intuitive IBC-Lite software, which not only displays the measured dose, but also assists and guides the user in performing the daily quality checks to ensure the correct operation of the dose calibrator. Discover the Comecer Dose Calibrators: https://lnkd.in/effwVEdr #ComecerForRadiopharma #NuclearMedicine

Did you know there are several types of pharmacy specialization? Discover each type and learn how to decide which one is right for you. Will you head to a clinic? A nuclear lab? Learn more using the link below. https://loom.ly/1YRyma0 #pharmacyspecialization #pharmacist #pharmacylife #ShiftPosts #nuclearpharmacist #clinicalpharmacist

Just attended an insightful webinar on nuclear pharmacy in a hospital setting. The session offered a deep dive into the latest advancements and practical applications of nuclear pharmacy in patient care. It was a fantastic opportunity to learn from industry experts and gain a better understanding of this critical field. Looking forward to applying these insights in my professional journey. #NuclearPharmacy #Healthcare #ProfessionalDevelopmen. #hospitalPharmacy #Pharmacist

🔗PHSE joins Nuclear Medicine Europe, the Industrial Association representing the leading pharmaceutical and imaging equipment companies in the field of nuclear medicine throughout Europe. Today's handshake at #EANM2024 Congress between Martinus Blauwhoff, President of Nuclear Medicine Europe, and Paul Rice, Chief Development Officer of PHSE International, kicks off the valuable #partnership.   “We have identified the Nuclear Medicine Europe Association as an opportunity to engage with industry experts, ranging from pharmaceutical companies to reactor operators worldwide, which we see as an essential part of our continuous improvement in offering highly specialised global transport services for the radiopharmaceutical market. Our first-hand involvement in working groups on topics of mutual interest, ranging from #SecurityOfSupply, #Therapy, #Regulatory Affairs & Quality, and the #Transport, will hopefully help bring real value to the complex radiopharmaceutical supply chain. While in the past drug distribution was considered the last chain in the manufacturing process, we strongly believe that logistics is increasingly a key asset and critical success factor in meeting the association’s challenges of #Innovation, #HealthcareForEveryone and #PatientSafety within the sector. The three fundamental pillars that drive our daily actions as well”, said Paul Rice. #DeliveringRadiopharmaceuticals #NewPartnership #NuclearMedicineEurope #PHSE #EANM2024

The European Association of Nuclear Medicine (EANM) and Nuclear Medicine Europe (NMEU) express disappointment over the recent European Parliament vote on the #Pharmaceutical #Regulation and Directive, which did not incorporate their proposed amendments aimed at updating the regulatory framework for #radiopharmaceuticals. Despite the pivotal role #NuclearMedicine plays in modern healthcare, especially in cancer care as recognized by EU initiatives like the SAMIRA Action Plan, the current legislative approach fails to acknowledge the significant advancements in radiopharmaceuticals since 2004. This oversight poses challenges to the industry and clinical sectors, leading to uncertainties and reduced availability of radiopharmaceuticals across Europe. EANM and Nuclear Medicine Europe advocate for a regulatory framework that aligns with the evolving landscape of Nuclear Medicine, emphasizing the need for updated definitions and provisions to support the growth and accessibility of radiopharmaceuticals. They call upon policymakers to reconsider these developments and ensure that the revised legislation reflects the advancements in Nuclear Medicine, ultimately benefiting patients across the EU. Download the full statement : https://lnkd.in/ewenrYx

Units of Measurement for Radioactive Material Used in Nuclear Medicine and Radiopharmaceutical Manufacturing. #NuclearMedicine #Radiopharmaceuticals #RadiationSafety #HealthcareInnovation #MedicalPhysics